Apellis Pharmaceuticals Inc. (APLS)

factsheet Factsheet
  • Value Research Rating market-capitalisation-info
    Not Applicable
  • Market Capitalisation market-capitalisation-info $8,150 Mln
  • Price to Earnings Ratio price-to-earning --
  • 12 Month Earnings monthly-earning $-166 Mln

Apellis Pharmaceuticals Inc. (APLS) Share Price

$67.85

As on 20-Feb-2024 16:00 EST

up-down-arrow $-0.93-1.35%

  • Prev Close info

    $68.78

  • Day's Openinfo

    $68.07

  • Today's Highinfo

    $69.80

  • Today's Lowinfo

    $67.25

  • Today's Volumeinfo

    853,772

  • 52 Week rangeinfo

    $19.83 - 94.75

Please wait...

Apellis Pharmaceuticals Inc. (APLS) Stock Performance

YTD
1 Month
3 Months
1 Year
3 Years
5 Years
10 Years
Apellis Pharmaceuticals (APLS)
13.35 6.35 38.19 22.27 14.06 36.40 --
S&P BSE Sensex*
0.53 1.68 10.61 19.66 12.59 15.22 13.46
S&P Small-Cap 600#
-5.82 -5.34 -13.73 -6.30 5.30 2.98 5.53
As on 20-Feb-2024  |  *As on 21-Feb-2024  |  #As on 26-Oct-2023
2023
2022
2021
2020
2019
2018
Apellis Pharmaceuticals (APLS)
15.76 9.37 -17.34 86.81 132.15 -39.05
S&P Small-Cap 600
13.89 -17.42 25.27 9.57 20.86 -9.70
S&P BSE Sensex
18.74 4.44 21.99 15.75 14.38 5.87

Valuation Score

Stock
Peer Median
Please wait...

Growth & Efficiency

Stock
Peer Median
Please wait...

Solvency

Is there a threat to this company's solvency in the future?

Financial Manipulation

Can creative accounting be detected through the financial numbers?

Apellis Pharmaceuticals Inc. (APLS) Peer Comparison

search
search
search
search
    Please wait...

    Valuation Chart of Apellis Pharmaceuticals Inc. (APLS)

      Please wait...
        Please wait...

        Financials

        Please wait...
        Please wait...
        Please wait...

        Shareholding Pattern

        Other details of Apellis Pharmaceuticals Inc. (APLS)

        Co-Founder, President, CEO & Director

        Dr. Cedric Francois M.D., Ph.D.

        Co-Founder & Chief Scientific Officer

        Dr. Pascal Deschatelets Ph.D.

        Headquarters

        Waltham, MA

        FAQs for Apellis Pharmaceuticals Inc. (APLS)

        The total asset value of Apellis Pharmaceuticals Inc. (APLS) stood at $ 1,004 Mln as on 30-Sep-23

        The share price of Apellis Pharmaceuticals Inc. (APLS) is $67.85 (NASDAQ) as of 20-Feb-2024 16:00 EST. Apellis Pharmaceuticals Inc. (APLS) has given a return of 14.06% in the last 3 years.

        Apellis Pharmaceuticals Inc. (APLS) has a market capitalisation of $ 8,150 Mln as on 16-Feb-2024. As per Value Research classification, it is a Small Cap company.

        The P/B ratio of Apellis Pharmaceuticals Inc. (APLS) is 35.10 times as on 16-Feb-2024, a 12.82% premium to its peers’ median range of 2.54 times.

        Since, TTM earnings of Apellis Pharmaceuticals Inc. (APLS) is negative, P/E ratio is not available.

        Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
        Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
        Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
        Step 4. Search for the Apellis Pharmaceuticals Inc. (APLS) and enter the required number of quantities and click on buy to purchase the shares of Apellis Pharmaceuticals Inc. (APLS).

        Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, cold agglutinin disease, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, amyotrophic lateral sclerosis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy (GA). The company also develops APL-2006, a bispecific C3 and VEGF inhibitor for treating wet age-related macular degeneration and GA; APL-1030, a C3 inhibitor for the treatment of various neurodegenerative diseases; and the combination of EMPAVELI and a small interfering RNA for reducing the production of C3 proteins by the liver. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts. Address: 100 Fifth Avenue, Waltham, MA, United States, 02451

        The CEO & director of Dr. Cedric Francois M.D., Ph.D.. is Apellis Pharmaceuticals Inc. (APLS), and CFO & Sr. VP is Dr. Pascal Deschatelets Ph.D..

        The promoters of Apellis Pharmaceuticals Inc. (APLS) have pledged 0% of the total equity as on Sep-23.

        Apellis Pharmaceuticals Inc. (APLS) Ratios
        Return on equity(%)
        -188.1
        Return on capital employed(%)
        --
        Debt-to-equity ratio
        0.4
        Dividend yield(%)
        0

        No, TTM profit after tax of Apellis Pharmaceuticals Inc. (APLS) was $-166 Mln.

        Edit peer-selector-edit
        Please wait...
        Please wait...

        Key Facts

        • Market cap market-cap-information $8,150.43 Mln
        • Revenue (TTM)revenue-information $261.66 Mln
        • Earnings (TTM) earning-information $-165.99 Mln
        • Cash date-information $452.41 Mln
        • Total Debt info $109.58 Mln
        • Insider's Holding 13.47%
        • Liquidity liquidity High
        • 52 Week range week-range $19.83 - 94.75
        • Shares outstanding share-outstanding 118,500,000
        • 10 Years Aggregate:

          CFO: $-2,318.74 Mln

          EBITDA: $-1,790.34 Mln

          Net Profit: $-2,922.20 Mln

        About The Company

        • IPO Date 09-Nov-2017
        • Co-Founder, President, CEO & Director Dr. Cedric Francois M.D., Ph.D.
        • Co-Founder & Chief Scientific Officer Dr. Pascal Deschatelets Ph.D.
        • Listing key-listing NASDAQ: APLS
        • Country United States
        • Headquarters headquarters Waltham, MA
        • Website website https://www.apellis.com
        • Business

          Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory...  diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, cold agglutinin disease, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, amyotrophic lateral sclerosis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy (GA). The company also develops APL-2006, a bispecific C3 and VEGF inhibitor for treating wet age-related macular degeneration and GA; APL-1030, a C3 inhibitor for the treatment of various neurodegenerative diseases; and the combination of EMPAVELI and a small interfering RNA for reducing the production of C3 proteins by the liver. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts. Address: 100 Fifth Avenue, Waltham, MA, United States, 02451  Read more

        share-fund-plan-icon